Maybe not. PWS is a crowded field - NEU may not be able to achieve the first mover advantage they've experienced in Rett and hopefully in PHS & Phelan-McDermid.
So I accept the reasons given for halting the trial, but it might also be the fact that some of the other indications Neuren has been testing through mouse models are more promising - and in diseases with no or little competition.
I can't wait to see what those indications may be, and what the mouse models are suggesting
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-67
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |